herbal-medicine-compliance

name	herbal-medicine-compliance
description	Use when selling herbal medicines, botanical drugs, traditional plant remedies, Ayurvedic products, TCM (Traditional Chinese Medicine), Kampo, or specific botanicals (Echinacea, Ginseng, Saw Palmetto, Turmeric, Ashwagandha, CBD, Kratom) in any market, navigating Directive 2004/24/EC THMPD, MHRA THR, FDA botanical drug pathway, BELFRIT lists, or per-plant restrictions

Herbal Medicine Compliance

Full regulatory workflow for botanical and herbal medicinal products. Sits between pharmaceutical, food supplement, and traditional medicine frameworks — wrong classification adds 3-7 years to launch.

Decision Flow

digraph {
  rankdir=TB; node [shape=box style=rounded fontsize=10];
  classify [label="1. Classify product:\nmedicine / supplement / cosmetic\n/ TCM / Kampo / food"];
  plant [label="2. Per-plant check:\nbanned, restricted, monograph,\nnovel food status"];
  framework [label="3. Pick framework:\nTHMPD 2004/24, DSHEA,\nNMPA TCM, BELFRIT, ANSES,\nKampo monograph"];
  quality [label="4. Quality control:\nadulteration, heavy metals,\npesticide MRLs, microbial"];
  evidence [label="5. Evidence: 30y use\n(15y EU) for THMP, or\nclinical for botanical drug"];
  label [label="6. Labeling: no disease claims,\nDSHEA disclaimer, THR mark"];
  reg [label="7. Notification / registration\nper market"];
  sell [label="8. Place on market"];
  classify -> plant -> framework -> quality -> evidence -> label -> reg -> sell;
}

EU -- Traditional Herbal Medicinal Products Directive (THMPD) 2004/24/EC

Aspect	Detail
Legal basis	Directive 2004/24/EC amending Directive 2001/83/EC on medicinal products for human use
Eligibility	Herbal medicine in use for ≥30 years total, ≥15 years in EU
Indications	Only minor self-limiting conditions (cough, indigestion, joint discomfort, mild anxiety). NO serious disease claims
Authority	National competent authority + EMA HMPC (Committee on Herbal Medicinal Products)
Monographs	HMPC publishes Community Herbal Monographs (CHMs) and EU List entries — once on list, simplified registration
Documentation	Quality dossier (CTD Module 3) + bibliographic evidence of safety + traditional use evidence (30y/15y)
GMP	EU GMP Part II for active substances, Part I for finished products. Inspections required
Marking	Product marked "Traditional herbal medicinal product for use in [indication] exclusively based upon long-standing use"
Pharmacovigilance	Full PSUR + ICSR reporting obligations (same as authorized medicines)
Cost	EUR 50,000-200,000 per dossier; EUR 5,000-25,000 per MS registration fee
Timeline	12-24 months

Key HMPC Monographs in Force (2026)

Botanical	Latin	Indication scope
Echinacea purpurea	Echinaceae purpureae herba	Common cold
Valerian	Valerianae radix	Mild nervous tension, sleep
St John's wort	Hyperici herba	Mild depressive symptoms (well-established use) / mild tension (traditional)
Ginkgo	Ginkgo folium	Vertigo, tinnitus, cognitive symptoms
Ginger	Zingiberis rhizoma	Motion sickness
Milk thistle	Silybi mariani fructus	Liver function support
Saw palmetto	Sabalis serrulatae fructus	BPH urinary symptoms
Hawthorn	Crataegi folium cum flore	Cardiac symptoms
Peppermint	Menthae piperitae aetheroleum	IBS, dyspepsia

US -- Two Distinct Paths

Path 1: Dietary Supplement (DSHEA 1994)

Aspect	Detail
Legal basis	Dietary Supplement Health and Education Act, codified in 21 USC 321(ff), 343, 350b
FDA notification	NDI (New Dietary Ingredient) notification 75 days before marketing if ingredient marketed AFTER Oct 15, 1994
Old Dietary Ingredients	Pre-DSHEA ingredients exempt from NDI notification (list maintained informally by industry)
Claims	Structure/function claims allowed ("supports immune function"). Disease claims PROHIBITED. Required disclaimer "This statement has not been evaluated by FDA"
GMP	21 CFR 111 cGMP for dietary supplements — mandatory since 2010
Adverse event reporting	Mandatory within 15 days of serious AE (21 USC 379aa-1)
Cost	NDI: USD 30,000-150,000 (toxicology dossier). GMP audit: USD 50,000-200,000 annual

Path 2: Botanical Drug (FDA Guidance 2016)

Aspect	Detail
Pathway	NDA (New Drug Application) under FD&C Act
Special guidance	"Botanical Drug Development Guidance for Industry" — December 2016
Approvals to date	Only 2 approved: Veregen (sinecatechins, 2006) + Mytesi/Fulyzaq (crofelemer, 2012). Several Phase III in progress
Path A (well-known botanical)	Reduced CMC + non-clinical requirements
Cost	USD 50M-300M including Phase III
Timeline	7-12 years

UK -- MHRA Traditional Herbal Registration (THR)

Aspect	Detail
Legal basis	Human Medicines Regulations 2012 (SI 1916), Part 7 — UK transposition of THMPD
Mark	THR mark on packaging — required + distinguishable from POM (prescription) + GSL (general sales)
Eligibility	30 years use total, 15 years in EU + UK (UK still recognizes EU history for pre-Brexit data)
Indications	Only minor self-limiting conditions
Fee	GBP 3,750 application + GBP 50,000-150,000 dossier prep
Renewal	5-year renewal cycle
Brexit divergence	UK accepting EMA HMPC monographs but assessing independently

Germany -- Kommission E + AMG

Aspect	Detail
Kommission E	Federal Health Office expert panel — published 380 herbal monographs 1978-1994 (still authoritative reference globally)
Apothekenpflichtig vs Freiverkäuflich	Prescription-only / pharmacy-only / freely sellable — German Pharmacy Operations Regulation
OTC herbal market	One of largest globally — EUR 1.5B/year
AMG (Arzneimittelgesetz)	German Medicines Act — interfaces with EU rules. National additional standards
BfArM	Federal Institute for Drugs and Medical Devices — assesses herbal medicine registrations
Standard authorization	Allowed for products fulfilling Kommission E monograph criteria — simpler path

France -- ANSES + Plantes Médicinales List

Aspect	Detail
148 medicinal plants	Annex of Decree 2008-841 — plants authorized for general sale outside pharmacy. Within pharmacy: full Pharmacopoeia
Pharmacopée française	French Pharmacopoeia — plant monographs, quality standards
ANSES	French Agency for Food, Environmental and Occupational Health Safety — supplements
Telemed declaration	Food supplement declaration required before marketing (Décret 2006-352) — ANSES portal
Pharmacy monopoly	Pharmacists hold monopoly on 540+ medicinal plants. Selling outside the 148-list outside pharmacy = practicing pharmacy illegally
DGCCRF enforcement	Regular sweeps of online supplement sellers — annual seizures

Italy / Belgium -- BELFRIT List

Aspect	Detail
BELFRIT	Belgium, France, Italy harmonized list — botanical supplements
Status	1,028 plants on harmonized list (consolidated 2014, updated 2018)
Use	Each plant categorized: permitted, restricted with conditions, prohibited
Scope	Italy: Decreto 9 luglio 2012 — uses BELFRIT-derived list (1,231 plants)
Belgium: AR 29 août 1997 botanicals list
France: Plantes Plantes 148-list overlaps but is narrower

China -- TCM Regulation

Aspect	Detail
NMPA Drug Administration Law (2019 revision)	TCM (Traditional Chinese Medicine) as registered drug category
Chinese Pharmacopoeia (Ph. Chin.)	2025 edition — 5,000+ monographs
TCM categories: Class 1 (new TCM) — full clinical. Class 2 (compound preparations from authorized herbs). Class 3 (proprietary TCM with classical formula record)
Classical Famous Formula Pathway (since 2017)	100+ historical formulas — simplified registration (no Phase III required if classical)
Imported TCM	Foreign TCM products require full NMPA registration. CFDA factory audit
Cost	CNY 5M-50M depending on category
Timeline	18 months (classical formula) to 6+ years (Class 1 new TCM)

Japan -- Kampo

Aspect	Detail
Kampo medicines	Japanese adaptation of Chinese herbal medicine — ~148 formulas reimbursed by national health insurance
Dual classification	Some Kampo are "ethical drugs" (prescription) reimbursed by NHI. Others are OTC under Pharmaceutical Affairs Law
MHLW notification	Required. Standards based on Japanese Pharmacopoeia (JP XVIII, 2021) + Kampo-specific monographs
Marketing Authorization Holder	Japan-based entity
GMP	Japan-specific GMP for Kampo manufacturers

WHO + Quality Standards

Standard	Coverage
WHO Guidelines on Good Agricultural and Collection Practices (GACP)	2003 — quality from farm
WHO Guidelines on Quality Control Methods for Herbal Materials	2011 — testing protocols
WHO Monographs on Selected Medicinal Plants	Volumes 1-4 — 118 plants
USP-NF Botanical	US Pharmacopoeia monographs
EP / Ph. Eur. monographs	European Pharmacopoeia — 270+ plant monographs
BP (British Pharmacopoeia)	UK monographs (largely aligned EP)

Contamination Limits

Heavy Metals (typical, EP Ch 5.20)

Metal	Limit (mg/kg dry weight)
Lead (Pb)	≤5.0
Cadmium (Cd)	≤1.0 (≤0.5 if daily intake >100 g)
Mercury (Hg)	≤0.1
Arsenic (As) inorganic	≤5.0

Pesticide Residues -- Reg 396/2005

• Default 0.01 mg/kg for non-authorized pesticides
• Plant-specific MRLs in Annex IV
• Higher tolerance for dried herbs (concentration factor up to 10x)

Microbial Limits (EP 5.1.4 / 5.1.8)

Use	TAMC	TYMC	Bile-tolerant Gram-neg	Salmonella
Herbal teas (boiled use)	10⁷ CFU/g	10⁵ CFU/g	10⁴ CFU/g	Absent 25 g
Herbal medicines (not boiled)	10⁵ CFU/g	10⁴ CFU/g	10³ CFU/g	Absent 25 g

Adulteration Testing

Method	Application
HPLC-UV / DAD	Marker compound identification (e.g., echinacoside in Echinacea, withanolides in Ashwagandha)
HPTLC	Pharmacopoeial identification — many EP monographs use TLC fingerprint
DNA barcoding	Species authentication (ITS2, matK, rbcL markers). Standard at Health Canada NHP, USP, increasingly EU
NMR fingerprinting	Whole-extract authentication
ICP-MS	Heavy metals quantification
GC-MS	Pesticides + essential oil analysis

Per-Plant Regulation Table (high-priority botanicals 2026)

Botanical	EU Status	US Status	UK	Restrictions
Echinacea purpurea/angustifolia	HMPC monograph, THMP	DSHEA — old ingredient	THR available	Pollen allergy warning
Ginseng (Panax ginseng)	HMPC monograph	DSHEA — old ingredient	THR available	Anticoagulant interaction warning
Saw palmetto (Serenoa repens)	HMPC monograph, THMP	DSHEA	THR available	Anti-androgen — male users only by precaution
Turmeric (Curcuma longa)	Food + supplement; high-dose >300 mg curcuminoids: hepatotoxicity warning per ANSES + Italian sales suspended 2019, returned 2020 with restriction	DSHEA — black-box warning emerging	Supplement; MHRA monitoring	Bile duct obstruction contraindication
Ashwagandha (Withania somnifera)	Food supplement most MS; Denmark + Sweden + Norway issued risk assessments 2020-2024 warning of thyroid + hepatotoxic risk + 17 case reports; FR limited 2024	DSHEA	Supplement; MHRA monitoring	Pregnancy contraindication; thyroid + hepatic warning
St John's wort (Hypericum perforatum)	Well-established medicine in DE/AT; THMP elsewhere	OTC supplement; FDA warning on drug interactions	THR + POM (prescription strengths)	Major CYP3A4 inducer — contraceptive failure, immunosuppressant + antiretroviral interactions
CBD (Cannabidiol)	Novel food (since 2019 EFSA decision). UK + EU MS authorizing case-by-case. THC <0.2% (EU) or 0.3% (US)	Hemp-derived legal under 2018 Farm Bill (<0.3% THC). FDA: not approved as supplement — enforcement discretion. Epidiolex (purified CBD) is prescription drug	Novel food authorization required by FSA; >50 products under assessment	Heavy state variation US; Italy banned synthetic CBD 2023
Kratom (Mitragyna speciosa)	NOT authorized as supplement; controlled in DK/SE/FI/LV/LT/PL/RO/IT (since 2016)	Federal: not scheduled but FDA import alert 54-15; State bans: AL, AR, IN, RI, VT, WI. Regulated supplement: TN, GA, KY, NV (KCPA)	Class B controlled (2024 update under Psychoactive Substances Act 2016)	High abuse + dependence potential
Kava (Piper methysticum)	Lifted EU ban in 2007 after WHO review; still restricted in UK, DE	Banned in some states; FDA consumer advisory	Banned for supplements; allowed traditional cultural use	Hepatotoxicity history